FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381943542> ?p ?o ?g. }

• W4381943542 abstract "Two cycles of neoadjuvant PD-1 blockade plus chemotherapy induced favorable pathological response and tolerant toxicity in patients with locally advanced esophageal squamous cell carcinoma (ESCC). However, approximately 25% of patients relapsed within 1 year after surgery, indicating that a short course of treatment may not be sufficient. Therefore, exploring the effects of intensive treatment is needed for optimal clinical outcomes.Locally advanced ESCC patients were administered three cycles of camrelizumab plus nab-paclitaxel and capecitabine, followed by thoracoscopic esophagectomy. The primary endpoint was pathologic response. Secondary endpoints included safety, feasibility, radiologic response, survival outcomes, and immunologic/genomic correlates of efficacy.Forty-seven patients were enrolled in the study. Forty-two patients received surgery, and R0 resection was achieved in all cases. The complete and major pathological response rates were 33.3% and 64.3%, respectively, and the objective response rate was 80.0%. Three cycles of treatment significantly improved T down-staging compared to two cycles (P = 0.03). The most common treatment-related adverse events were grades 1-2, and no surgical delay was reported. With a median follow-up of 24.3 months, the 1-year disease-free survival and overall survival rates were both 97.6%, and the 2-year disease-free survival and overall survival rates were 92.3% and 97.6%, respectively. Three patients experienced disease recurrence or metastasis ranging from 12.5 to 25.8 months after surgery, and one patient died 6 months after surgery due to cardiovascular disease. Neither programmed death-ligand 1 expression nor tumor mutational burden was associated with pathological response. An increased infiltration of CD56dim natural killer cells in the pretreatment tumor was correlated with better pathological response in the primary tumor.It seems probable that intensive cycles of neoadjuvant camrelizumab plus nab-paclitaxel and capecitabine increased tumor regression and improved survival outcomes. Randomized controlled trials with larger sample sizes and longer follow-up periods are needed to validate these findings. Trial registration Chinese Clinical Trial Registry, ChiCTR2000029807, Registered February 14, 2020, https://www.chictr.org.cn/showproj.aspx?proj=49459 ." @default.
• W4381943542 created "2023-06-26" @default.
• W4381943542 creator A5010793258 @default.
• W4381943542 creator A5012628087 @default.
• W4381943542 creator A5024877519 @default.
• W4381943542 creator A5031789224 @default.
• W4381943542 creator A5033639859 @default.
• W4381943542 creator A5039618601 @default.
• W4381943542 creator A5040210858 @default.
• W4381943542 creator A5048392701 @default.
• W4381943542 creator A5051112014 @default.
• W4381943542 creator A5051861992 @default.
• W4381943542 creator A5054052985 @default.
• W4381943542 creator A5065225564 @default.
• W4381943542 creator A5076524787 @default.
• W4381943542 creator A5078275783 @default.
• W4381943542 creator A5081122407 @default.
• W4381943542 creator A5085161419 @default.
• W4381943542 date "2023-06-24" @default.
• W4381943542 modified "2023-10-16" @default.
• W4381943542 title "Intensive cycles of neoadjuvant camrelizumab combined with chemotherapy in locally advanced esophageal squamous cell carcinoma: a single-arm, phase II trial" @default.
• W4381943542 cites W1975912072 @default.
• W4381943542 cites W2019607817 @default.
• W4381943542 cites W2051766264 @default.
• W4381943542 cites W2083360790 @default.
• W4381943542 cites W2087675944 @default.
• W4381943542 cites W2099567806 @default.
• W4381943542 cites W2143826746 @default.
• W4381943542 cites W2150510406 @default.
• W4381943542 cites W2272984102 @default.
• W4381943542 cites W2439738364 @default.
• W4381943542 cites W2789258259 @default.
• W4381943542 cites W2798160602 @default.
• W4381943542 cites W2803906315 @default.
• W4381943542 cites W2809140578 @default.
• W4381943542 cites W2885107163 @default.
• W4381943542 cites W2889646458 @default.
• W4381943542 cites W2891344378 @default.
• W4381943542 cites W2916647762 @default.
• W4381943542 cites W2962618676 @default.
• W4381943542 cites W2982617740 @default.
• W4381943542 cites W2998795792 @default.
• W4381943542 cites W3000311037 @default.
• W4381943542 cites W3010341100 @default.
• W4381943542 cites W3015035400 @default.
• W4381943542 cites W3027588727 @default.
• W4381943542 cites W3049733355 @default.
• W4381943542 cites W3115014139 @default.
• W4381943542 cites W3135761044 @default.
• W4381943542 cites W3139006719 @default.
• W4381943542 cites W3167135167 @default.
• W4381943542 cites W3176554030 @default.
• W4381943542 cites W3190247361 @default.
• W4381943542 cites W3198128201 @default.
• W4381943542 cites W3200109370 @default.
• W4381943542 cites W3211279502 @default.
• W4381943542 cites W3212054009 @default.
• W4381943542 cites W3217286056 @default.
• W4381943542 cites W4206997993 @default.
• W4381943542 cites W4213141980 @default.
• W4381943542 cites W4220823757 @default.
• W4381943542 cites W4280643802 @default.
• W4381943542 cites W4281787927 @default.
• W4381943542 cites W4313219310 @default.
• W4381943542 cites W4363643601 @default.
• W4381943542 cites W4367362646 @default.
• W4381943542 doi "https://doi.org/10.1186/s12967-023-04273-6" @default.
• W4381943542 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37355621" @default.
• W4381943542 hasPublicationYear "2023" @default.
• W4381943542 type Work @default.
• W4381943542 citedByCount "0" @default.
• W4381943542 crossrefType "journal-article" @default.
• W4381943542 hasAuthorship W4381943542A5010793258 @default.
• W4381943542 hasAuthorship W4381943542A5012628087 @default.
• W4381943542 hasAuthorship W4381943542A5024877519 @default.
• W4381943542 hasAuthorship W4381943542A5031789224 @default.
• W4381943542 hasAuthorship W4381943542A5033639859 @default.
• W4381943542 hasAuthorship W4381943542A5039618601 @default.
• W4381943542 hasAuthorship W4381943542A5040210858 @default.
• W4381943542 hasAuthorship W4381943542A5048392701 @default.
• W4381943542 hasAuthorship W4381943542A5051112014 @default.
• W4381943542 hasAuthorship W4381943542A5051861992 @default.
• W4381943542 hasAuthorship W4381943542A5054052985 @default.
• W4381943542 hasAuthorship W4381943542A5065225564 @default.
• W4381943542 hasAuthorship W4381943542A5076524787 @default.
• W4381943542 hasAuthorship W4381943542A5078275783 @default.
• W4381943542 hasAuthorship W4381943542A5081122407 @default.
• W4381943542 hasAuthorship W4381943542A5085161419 @default.
• W4381943542 hasBestOaLocation W43819435421 @default.
• W4381943542 hasConcept C121608353 @default.
• W4381943542 hasConcept C126322002 @default.
• W4381943542 hasConcept C141071460 @default.
• W4381943542 hasConcept C143998085 @default.
• W4381943542 hasConcept C203092338 @default.
• W4381943542 hasConcept C2776694085 @default.
• W4381943542 hasConcept C2777297899 @default.
• W4381943542 hasConcept C2778292576 @default.
• W4381943542 hasConcept C2779742542 @default.
• W4381943542 hasConcept C530470458 @default.
• W4381943542 hasConcept C535046627 @default.

• next